Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
Bioxodes advances BIOX-101 into pivotal trials for intracerebral hemorrhage. Find out how this strategy could reshape stroke treatment pathways.
Pharma & Biotech
Pharma & Biotech
What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
Can darlifarnib overcome VEGF resistance in kidney cancer? Explore what Kura Oncology’s latest data could mean for future treatment strategies.
Pharma & Biotech
Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
Discover how FT839’s conditioning-free CAR T platform could reshape cancer and autoimmune treatment pathways. Read the full analysis now.
Pharma & Biotech
Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
Pharma & Biotech
What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.
Pharma & Biotech
Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
Savara’s molgramostim FDA review was extended to November 22, 2026. Read what this means for autoimmune PAP, launch timing, and regulatory risk.
Pharma & Biotech
How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem
Galderma has launched Regenerating Skin Nectar with TriHex+. Read why this matters for peri-procedural skincare, clinics, and regenerative aesthetics.
Pharma & Biotech
Why CUE-401’s IMMUNOLOGY2026 data could matter for autoimmune drug pipelines
Cue Biopharma, Inc. unveils new CUE-401 data. Find out what this means for autoimmune therapy development and the regulatory path ahead.
Pharma & Biotech
Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
Pharma & Biotech
How Boehringer Ingelheim and Zai Lab are advancing a two-pronged DLL3 attack in SCLC
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.